U.S. markets open in 9 hours 27 minutes

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.07+0.12 (+0.57%)
At close: 4:00PM EDT

ACADIA Pharmaceuticals Inc.

12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871
http://www.acadia-pharm.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees640

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephen R. DavisCEO & Director1.36M7.98M1961
Dr. Srdjan R. StankovicPres1.23MN/A1957
Ms. Elena H. Ridloff C.F.A., CFAExec. VP & CFO689.09k1.22M1980
Mr. Austin D. KimExec. VP, Gen. Counsel & Sec.700.8k480.9k1964
Mr. James K. KiharaVP, Corp. Controller & Principal Accounting OfficerN/AN/A1980
Mr. Bob MischlerSr. VP of Strategy & Technology OperationsN/AN/AN/A
Mr. Mark C. JohnsonVP of Investor RelationsN/AN/AN/A
Ms. Stephanie FaganSr. VP of Corp. Affairs & Chief Communications OfficerN/AN/AN/A
Ms. Charmaine LykinsSr. VP of Global Product Planning & Chief Marketing OfficerN/AN/AN/A
Dr. Mary Ellen TurnerSr. VP of Pharmacovigilance & Corp. Safety OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Corporate Governance

ACADIA Pharmaceuticals Inc.’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.